Review



human neutralizing fgfr1 mab765  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems human neutralizing fgfr1 mab765
    Figure 1: Proximity between apelin and <t>FGFR1</t> suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.
    Human Neutralizing Fgfr1 Mab765, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human neutralizing fgfr1 mab765/product/R&D Systems
    Average 93 stars, based on 10 article reviews
    human neutralizing fgfr1 mab765 - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis through Suppression of TGF β -Induced Endothelial-to-Mesenchymal Transition."

    Article Title: The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis through Suppression of TGF β -Induced Endothelial-to-Mesenchymal Transition.

    Journal: Oxidative medicine and cellular longevity

    doi: 10.1155/2023/5012474

    Figure 1: Proximity between apelin and FGFR1 suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.
    Figure Legend Snippet: Figure 1: Proximity between apelin and FGFR1 suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.

    Techniques Used: In Situ, Western Blot

    Figure 4: CEBPA knockdown promotes TGFβ-mediated EndMT. (a) HMVECs were transfected with or without CEBPA siRNA for 48 h in the presence or absence of TGFβ2, and the VE-cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α-SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (b) HMVECs were transfected with CEBPA siRNA for 48 h in the presence or absence of TGFβ2 and apelin, and the VE- cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α- SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (c) HMVECs were treated with TGFβ2 for 15 min or 48 h with or without preincubation with apelin for 2 h, and the CEBPA levels were analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. (d) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of apelin, and the CEBPA levels was analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. Immunofluorescence analysis of CD31 (e) and α-SMA (f) coexpression in HUVECs following TGFβ2 or/and apelin or/and CEBPA siRNA treatment. For each slide, images of six different fields of view at ×200 magnification were evaluated. The scale bar is 50 μm in each panel.
    Figure Legend Snippet: Figure 4: CEBPA knockdown promotes TGFβ-mediated EndMT. (a) HMVECs were transfected with or without CEBPA siRNA for 48 h in the presence or absence of TGFβ2, and the VE-cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α-SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (b) HMVECs were transfected with CEBPA siRNA for 48 h in the presence or absence of TGFβ2 and apelin, and the VE- cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α- SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (c) HMVECs were treated with TGFβ2 for 15 min or 48 h with or without preincubation with apelin for 2 h, and the CEBPA levels were analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. (d) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of apelin, and the CEBPA levels was analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. Immunofluorescence analysis of CD31 (e) and α-SMA (f) coexpression in HUVECs following TGFβ2 or/and apelin or/and CEBPA siRNA treatment. For each slide, images of six different fields of view at ×200 magnification were evaluated. The scale bar is 50 μm in each panel.

    Techniques Used: Knockdown, Transfection, Western Blot



    Similar Products

    93
    R&D Systems human neutralizing fgfr1 mab765
    Figure 1: Proximity between apelin and <t>FGFR1</t> suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.
    Human Neutralizing Fgfr1 Mab765, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human neutralizing fgfr1 mab765/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human neutralizing fgfr1 mab765 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    R&D Systems human neutralizing fgfr1 n fgfr1
    Figure 1: Proximity between apelin and <t>FGFR1</t> suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.
    Human Neutralizing Fgfr1 N Fgfr1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human neutralizing fgfr1 n fgfr1/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    human neutralizing fgfr1 n fgfr1 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    R&D Systems human neutralizing fgfr1
    Proximity between AcSDKP and <t>FGFR1</t> inhibits the TGF β /smad signaling pathway in HMVECs. ( a ) HMVECs were treated with N-FGFR1 (1.5 μ g/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. ( b and c ) HMVECs were treated with TGF β 2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGF β R1, TGF β R2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin levels from each group ( n =6) were analyzed. ( d and e ) HMVECs were incubated with TGF β 2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (Ac DSPK , AcSDK A , Ac A DKP) (100 nM) for 2 h. The p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin protein levels were analyzed by western blot
    Human Neutralizing Fgfr1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human neutralizing fgfr1/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human neutralizing fgfr1 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    ImClone Inc human anti-fgfr1 neutralizing antibody clone fr1-h7
    Proximity between AcSDKP and <t>FGFR1</t> inhibits the TGF β /smad signaling pathway in HMVECs. ( a ) HMVECs were treated with N-FGFR1 (1.5 μ g/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. ( b and c ) HMVECs were treated with TGF β 2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGF β R1, TGF β R2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin levels from each group ( n =6) were analyzed. ( d and e ) HMVECs were incubated with TGF β 2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (Ac DSPK , AcSDK A , Ac A DKP) (100 nM) for 2 h. The p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin protein levels were analyzed by western blot
    Human Anti Fgfr1 Neutralizing Antibody Clone Fr1 H7, supplied by ImClone Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human anti-fgfr1 neutralizing antibody clone fr1-h7/product/ImClone Inc
    Average 90 stars, based on 1 article reviews
    human anti-fgfr1 neutralizing antibody clone fr1-h7 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    ImClone Inc igg1 human anti-human fgfr1-specific neutralizing antibody (clone h7)
    Proximity between AcSDKP and <t>FGFR1</t> inhibits the TGF β /smad signaling pathway in HMVECs. ( a ) HMVECs were treated with N-FGFR1 (1.5 μ g/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. ( b and c ) HMVECs were treated with TGF β 2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGF β R1, TGF β R2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin levels from each group ( n =6) were analyzed. ( d and e ) HMVECs were incubated with TGF β 2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (Ac DSPK , AcSDK A , Ac A DKP) (100 nM) for 2 h. The p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin protein levels were analyzed by western blot
    Igg1 Human Anti Human Fgfr1 Specific Neutralizing Antibody (Clone H7), supplied by ImClone Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igg1 human anti-human fgfr1-specific neutralizing antibody (clone h7)/product/ImClone Inc
    Average 90 stars, based on 1 article reviews
    igg1 human anti-human fgfr1-specific neutralizing antibody (clone h7) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1: Proximity between apelin and FGFR1 suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.

    Journal: Oxidative medicine and cellular longevity

    Article Title: The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis through Suppression of TGF β -Induced Endothelial-to-Mesenchymal Transition.

    doi: 10.1155/2023/5012474

    Figure Lengend Snippet: Figure 1: Proximity between apelin and FGFR1 suppresses the TGFβ/Smad signaling pathway in HMVECs. (a) HMVECs were treated with TGFβ2 (5 ng/mL) or N-FGFR1 (1.5 μg/mL) for 48 h with or without preincubation with apelin (100 nM) for 2 h. The proximity between apelin and FGFR1 was then analyzed by the Duolink In Situ Assay. For each slide, images at a ×400 original magnification were obtained from six different areas. The scale bar is 60 μm in each panel. (b) HMVECs were treated with TGFβ2 (5 ng/mL) or with apelin (100 nM) for 48 h, and the p-Smad3, TGFβR1, TGFβR2, and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-Smad3/Smad3, TGFβR1/β-actin, TGFβR2/β-actin, and FGFR1/β-actin levels from each group (n = 5) was analyzed. (c) HMVECs were treated with or without apelin (100 nM) for 48 h, and the FGFR1 levels were analyzed by western blot. Densitometric analysis of the FGFR1/GADPH levels from each group (n = 5) was analyzed.

    Article Snippet: Human neutralizing FGFR1 (MAB765) was obtained from R&D Systems (Minneapolis, MN, USA).

    Techniques: In Situ, Western Blot

    Figure 4: CEBPA knockdown promotes TGFβ-mediated EndMT. (a) HMVECs were transfected with or without CEBPA siRNA for 48 h in the presence or absence of TGFβ2, and the VE-cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α-SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (b) HMVECs were transfected with CEBPA siRNA for 48 h in the presence or absence of TGFβ2 and apelin, and the VE- cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α- SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (c) HMVECs were treated with TGFβ2 for 15 min or 48 h with or without preincubation with apelin for 2 h, and the CEBPA levels were analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. (d) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of apelin, and the CEBPA levels was analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. Immunofluorescence analysis of CD31 (e) and α-SMA (f) coexpression in HUVECs following TGFβ2 or/and apelin or/and CEBPA siRNA treatment. For each slide, images of six different fields of view at ×200 magnification were evaluated. The scale bar is 50 μm in each panel.

    Journal: Oxidative medicine and cellular longevity

    Article Title: The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis through Suppression of TGF β -Induced Endothelial-to-Mesenchymal Transition.

    doi: 10.1155/2023/5012474

    Figure Lengend Snippet: Figure 4: CEBPA knockdown promotes TGFβ-mediated EndMT. (a) HMVECs were transfected with or without CEBPA siRNA for 48 h in the presence or absence of TGFβ2, and the VE-cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α-SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (b) HMVECs were transfected with CEBPA siRNA for 48 h in the presence or absence of TGFβ2 and apelin, and the VE- cadherin, α-SMA, vimentin, and SM22α levels were analyzed by western blot. Densitometric analysis of the VE-cadherin/GADPH, α- SMA/GADPH, vimentin/GADPH, and SM22α/GADPH levels from each group (n = 5) was analyzed. (c) HMVECs were treated with TGFβ2 for 15 min or 48 h with or without preincubation with apelin for 2 h, and the CEBPA levels were analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. (d) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of apelin, and the CEBPA levels was analyzed by western blot. Densitometric analysis of the CEBPA/GADPH level from each group (n = 5) was analyzed. Immunofluorescence analysis of CD31 (e) and α-SMA (f) coexpression in HUVECs following TGFβ2 or/and apelin or/and CEBPA siRNA treatment. For each slide, images of six different fields of view at ×200 magnification were evaluated. The scale bar is 50 μm in each panel.

    Article Snippet: Human neutralizing FGFR1 (MAB765) was obtained from R&D Systems (Minneapolis, MN, USA).

    Techniques: Knockdown, Transfection, Western Blot

    Proximity between AcSDKP and FGFR1 inhibits the TGF β /smad signaling pathway in HMVECs. ( a ) HMVECs were treated with N-FGFR1 (1.5 μ g/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. ( b and c ) HMVECs were treated with TGF β 2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGF β R1, TGF β R2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin levels from each group ( n =6) were analyzed. ( d and e ) HMVECs were incubated with TGF β 2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (Ac DSPK , AcSDK A , Ac A DKP) (100 nM) for 2 h. The p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin protein levels were analyzed by western blot

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: Proximity between AcSDKP and FGFR1 inhibits the TGF β /smad signaling pathway in HMVECs. ( a ) HMVECs were treated with N-FGFR1 (1.5 μ g/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. ( b and c ) HMVECs were treated with TGF β 2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGF β R1, TGF β R2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin levels from each group ( n =6) were analyzed. ( d and e ) HMVECs were incubated with TGF β 2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (Ac DSPK , AcSDK A , Ac A DKP) (100 nM) for 2 h. The p-smad3/smad3, TGF β R1/ β -actin, TGF β R2/ β -actin and FGFR1/ β -actin protein levels were analyzed by western blot

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: In Situ, Western Blot, Incubation

    AcSDKP suppresses TGF β /smad signaling and EndMT through the FGFR1/FRS2 pathway. ( a ) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF β R1 and TGF β R2 protein levels were analyzed by western blot. ( b ) HMVECs were treated with TGF β 2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF β R1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF β R1/ β -actin levels ( n =3) in each group was performed. ( c ) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF β 2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF β 2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 α , FSP1 and α -SMA protein levels were analyzed by western blot. ( d ) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 α and p-smad3 levels were analyzed by western blot. ( e ) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF β (1, 2, 3) (1.0 μ g/ml). The CD31, VE-cadherin, SM22 α , FSP1, TGF β R1, TGF β R2 and p-smad3 levels were analyzed by western blot

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: AcSDKP suppresses TGF β /smad signaling and EndMT through the FGFR1/FRS2 pathway. ( a ) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF β R1 and TGF β R2 protein levels were analyzed by western blot. ( b ) HMVECs were treated with TGF β 2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF β R1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF β R1/ β -actin levels ( n =3) in each group was performed. ( c ) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF β 2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF β 2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 α , FSP1 and α -SMA protein levels were analyzed by western blot. ( d ) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 α and p-smad3 levels were analyzed by western blot. ( e ) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF β (1, 2, 3) (1.0 μ g/ml). The CD31, VE-cadherin, SM22 α , FSP1, TGF β R1, TGF β R2 and p-smad3 levels were analyzed by western blot

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: Western Blot, Incubation, Transfection

    FGF2/FGFR1 mediates MAP4K4 signaling in endothelial cells. ( a ) Immunofluorescence microscopy analysis of P-MAP4K4 expression following FRS2 siRNA or TGF β 2 treatment. For each slide, images of six different fields of view at × 400 magnification were evaluated. The scale bar is 60 μ m in each panel. ( b and c ) HMVECs were treated with N-FGFR1 for 48 h or FGF2 for 24 h. The P-MAP4K4 levels were analyzed by western blot

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: FGF2/FGFR1 mediates MAP4K4 signaling in endothelial cells. ( a ) Immunofluorescence microscopy analysis of P-MAP4K4 expression following FRS2 siRNA or TGF β 2 treatment. For each slide, images of six different fields of view at × 400 magnification were evaluated. The scale bar is 60 μ m in each panel. ( b and c ) HMVECs were treated with N-FGFR1 for 48 h or FGF2 for 24 h. The P-MAP4K4 levels were analyzed by western blot

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: Immunofluorescence, Microscopy, Expressing, Western Blot

    The proximity between FGFR1 and P-MAP4K4 decreases in FGFR1-deficient cells. ( a ) HMVECs were treated with N-FGFR1 or TGF β 2 for 48 h. The proximity between FGFR1 and P-MAP4K4 was analyzed using the Duolink In Situ Assay. For each slide, images at × 400 original magnification were obtained from six different areas. ( b ) immunoprecipitation analysis with either a P-MAP4K4 or a FGFR1 antibody was performed and analyzed by western blot. Then, the FGFR1 and P-MAP4K4 levels with N-FGFR1 or TGF β 2 treatment were analyzed by western blot in endothelial cells

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: The proximity between FGFR1 and P-MAP4K4 decreases in FGFR1-deficient cells. ( a ) HMVECs were treated with N-FGFR1 or TGF β 2 for 48 h. The proximity between FGFR1 and P-MAP4K4 was analyzed using the Duolink In Situ Assay. For each slide, images at × 400 original magnification were obtained from six different areas. ( b ) immunoprecipitation analysis with either a P-MAP4K4 or a FGFR1 antibody was performed and analyzed by western blot. Then, the FGFR1 and P-MAP4K4 levels with N-FGFR1 or TGF β 2 treatment were analyzed by western blot in endothelial cells

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: In Situ, Immunoprecipitation, Western Blot

    MAP4K4 signaling is mediated by AcSDKP in a FGFR1/FRS2-dependent manner. ( a and b ) HMVECs were treated with N-FGFR1 for 48 h in the presence or absence of FGF2 or AcSDKP. P-MAP4K4 levels were analyzed by western blot. Densitometric analysis of P-MAP4K4 levels normalized to MAP4K4. For each group, n =3 were analyzed. ( c and d ) HMVECs were transfected with FRS2 siRNA for 48 h with or without FGF2 or AcSDKP treatment. P-MAP4K4 levels were analyzed by western blot. Densitometric analysis of P-MAP4K4 levels, normalized to MAP4K4. A total of n =3 from each group were analyzed

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: MAP4K4 signaling is mediated by AcSDKP in a FGFR1/FRS2-dependent manner. ( a and b ) HMVECs were treated with N-FGFR1 for 48 h in the presence or absence of FGF2 or AcSDKP. P-MAP4K4 levels were analyzed by western blot. Densitometric analysis of P-MAP4K4 levels normalized to MAP4K4. For each group, n =3 were analyzed. ( c and d ) HMVECs were transfected with FRS2 siRNA for 48 h with or without FGF2 or AcSDKP treatment. P-MAP4K4 levels were analyzed by western blot. Densitometric analysis of P-MAP4K4 levels, normalized to MAP4K4. A total of n =3 from each group were analyzed

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: Western Blot, Transfection

    AcSDKP inhibits TGF β /smad signaling and EndMT and restores the FGFR1 and P-MAP4K4 levels in diabetic hearts. ( a ) Immunofluorescence microscopy analysis of CD31/FGFR1 and CD31/P-MAP4K4 in the heart tissues from each group of mice. The scale bar is 60 μ m in each panel. The CD31 and FGFR1 double-labeled cells and the CD31 and P-MAP4K4 double-labeled cells in each visual field were assessed by fluorescence microscopy and quantified. For each section, images from six different fields of view at × 400 magnification were evaluated. ( b and c ) Immunofluorescence microscopy analysis of CD31/ α -SMA, VE-cadherin /SM22 α and CD31/p-smad3 expression levels in the heart tissues from each group of mice. The scale bar is 60 μ m in each panel. The CD31 and α -SMA double-labeled cells, the VE-cadherin and SM22 α double-labeled cells and the CD31 and p-smad3 double-labeled cells in each visual field were analyzed by fluorescence microscopy and quantified. For each section, images from six different fields of view at × 400 magnification were evaluated. Four mice from each group were analyzed. ( d ) Western blot analysis of the FGFR1, P-MAP4K4, TGF β 1, TGF β 2 and TGF β 3 levels in cardiac tissues. A representative blot from four independent experiments was shown. The densitometric analysis of western blot data was presented ( n =4). The diabetic mice are abbreviated as DM in the figure

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: AcSDKP inhibits TGF β /smad signaling and EndMT and restores the FGFR1 and P-MAP4K4 levels in diabetic hearts. ( a ) Immunofluorescence microscopy analysis of CD31/FGFR1 and CD31/P-MAP4K4 in the heart tissues from each group of mice. The scale bar is 60 μ m in each panel. The CD31 and FGFR1 double-labeled cells and the CD31 and P-MAP4K4 double-labeled cells in each visual field were assessed by fluorescence microscopy and quantified. For each section, images from six different fields of view at × 400 magnification were evaluated. ( b and c ) Immunofluorescence microscopy analysis of CD31/ α -SMA, VE-cadherin /SM22 α and CD31/p-smad3 expression levels in the heart tissues from each group of mice. The scale bar is 60 μ m in each panel. The CD31 and α -SMA double-labeled cells, the VE-cadherin and SM22 α double-labeled cells and the CD31 and p-smad3 double-labeled cells in each visual field were analyzed by fluorescence microscopy and quantified. For each section, images from six different fields of view at × 400 magnification were evaluated. Four mice from each group were analyzed. ( d ) Western blot analysis of the FGFR1, P-MAP4K4, TGF β 1, TGF β 2 and TGF β 3 levels in cardiac tissues. A representative blot from four independent experiments was shown. The densitometric analysis of western blot data was presented ( n =4). The diabetic mice are abbreviated as DM in the figure

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: Immunofluorescence, Microscopy, Labeling, Fluorescence, Expressing, Western Blot

    Schematic of the AcSDKP/FGFR1/MAP4K4 pathway suppression of TGF β /smad signaling and EndMT. In endothelial cells, the close proximity between AcSDKP and FGFR1 increased FGFR1 and induced its phosphorylation levels. Interacting with co-factor FRS2, FGFR1 recruited MAP4K4 and induced its phosphorylation. Subsequently, p-MAP4K4 suppressed integrin β 1 (integrin β 1 should be localized on the cell surface interacted with some of α integrins). Integrin β 1 was a potent activator of TGF- β signaling and also EndMT. Therefore, AcSDKP could inhibit EndMT through FGFR1-MAP4K4-dependent manner

    Journal: Cell Death & Disease

    Article Title: FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N -acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

    doi: 10.1038/cddis.2017.353

    Figure Lengend Snippet: Schematic of the AcSDKP/FGFR1/MAP4K4 pathway suppression of TGF β /smad signaling and EndMT. In endothelial cells, the close proximity between AcSDKP and FGFR1 increased FGFR1 and induced its phosphorylation levels. Interacting with co-factor FRS2, FGFR1 recruited MAP4K4 and induced its phosphorylation. Subsequently, p-MAP4K4 suppressed integrin β 1 (integrin β 1 should be localized on the cell surface interacted with some of α integrins). Integrin β 1 was a potent activator of TGF- β signaling and also EndMT. Therefore, AcSDKP could inhibit EndMT through FGFR1-MAP4K4-dependent manner

    Article Snippet: The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGF β (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA).

    Techniques: Phospho-proteomics